Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2012

HemaQuest Raises $13M to Fund Phase II Study with Sickle Cell/Thalassemia Drug

  • HemaQuest Pharmaceuticals raised $13 million in an extension to its Series B financing round led by existing investors. The firm will use the funds to carry out a Phase IIb study evaluating its lead short chain fatty acid derivative (SCFAD) compound HQK-1001 in patients with sickle cell disease.

    Seattle-based HemaQuest was established in 2007 to develop small molecule drugs for the treatment of serious hematologic disorders. The firm’s IP is centered on the SCFAD technology originally developed at Boston University School of Medicine. The platform comprises orally administered SCFADs that demonstrate epigenetic mechanisms of action to target the expression of key genes required to generate their therapeutic effects.

    Lead candidate HQK-1001 is designed to stimulate fetal hemoglobin expression and red blood cell production, and has already been evaluated in clinical trials in patients with sickle cell diseases and beta thalassemia. Orphan drug designation for both the sickle cell and thalassemia indications has been granted in the U.S. and Europe. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »